Touch Bionics, Livingston, Scotland, announced that preliminary results indicate the company achieved total revenues of £13.6 million (about US $20.7 million) in 2014, a 10 percent increase over 2013 results.
The company said its growth was driven by the continued success of the i-limb ultra revolution, and that the product has enjoyed significant success in the United States, its largest market. The company also said its recently introduced prosthetic flexible wrist for the i-limb, together with new versions of the biosim and my i-limb mobile apps, along with its new direct-sales approach in certain European markets, are expected to make an important contribution to the company’s continued growth in 2015.
“We are pleased with our 2014 performance and are proud that to-date more than 4,000 patients have benefitted from our technologies…,” said Ian Stevens, CEO, Touch Bionics.
